NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ENVB

Enveric Biosciences Inc

Apr 04 • 11:52AM ET

1.16

Dollar change -0.12
Percentage change -9.38	%

Healthcare • Biotechnology • USA • NASD

Peers: CMPS AVXL CYBN SAVA ATAI MNMD RLMD GHRS NURO

| Held by: PSIL VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-21.33	Insider Own	6.01%	Shs Outstand	2.47M	Perf Week	-21.09%
Market Cap	2.86M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.32M	Perf Month	-39.58%
Income	-9.57M	PEG	-	EPS next Q	-	Inst Own	2.91%	Short Float	10.39%	Perf Quarter	-80.17%
Sales	0.00M	P/S	-	EPS this Y	38.66%	Inst Trans	26.03%	Short Ratio	0.08	Perf Half Y	-81.73%
Book/sh	2.35	P/B	0.49	EPS next Y	-	ROA	-208.15%	Short Interest	0.24M	Perf Year	-92.34%
Cash/sh	0.91	P/C	1.28	EPS next 5Y	-	ROE	-356.82%	52W Range	1.13 - 15.45	Perf YTD	-78.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	57.47%	ROI	-601.14%	52W High	-92.49%	Beta	0.67
Dividend TTM	-	Quick Ratio	1.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2.65%	ATR (14)	0.21
Dividend Ex-Date	Apr 23, 2008	Current Ratio	1.84	EPS Y/Y TTM	82.47%	Oper. Margin	-	RSI (14)	29.39	Volatility	9.12% 8.51%
Employees	5	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	150.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	78.05%	Payout	-	Rel Volume	0.09	Prev Close	1.28
Sales Surprise	-	EPS Surprise	-40.00%	Sales Q/Q	-	Earnings	Mar 31 BMO	Avg Volume	2.84M	Price	1.16
SMA20	-26.70%	SMA50	-40.90%	SMA200	-79.51%	Trades		Volume	97,908	Change	-9.38%

Mar-31-25 08:00AM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 (Business Wire) -5.44%
Mar-17-25 01:40PM	Enveric Biosciences Participating in BIO-Europe Spring (Business Wire)
Mar-07-25 10:05AM	Enveric Biosciences launches RFP solicitation process for PsyAI trademark (TipRanks) -5.21%
Mar-06-25 10:00AM	Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark (Business Wire) -8.57%
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks) +32.08%
09:30AM	Loading…
Feb-27-25 09:30AM	Enveric Biosciences CEO Issues Letter to Shareholders (Business Wire) -7.83%
Feb-25-25 01:30PM	Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent (Business Wire) -13.87%
Feb-04-25 08:00AM	Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease (Business Wire)
Feb-03-25 05:00PM	Enveric Biosciences Announces Closing of $5 Million Public Offering (Business Wire) -13.40%
Jan-31-25 09:17AM	Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading (GuruFocus.com) -46.41%
Jan-30-25 08:14PM	Enveric Biosciences Announces Pricing of $5 Million Public Offering (Business Wire) -9.30%
04:01PM	Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office (Business Wire)
Jan-06-25 09:10AM	Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025" (Business Wire)
Dec-02-24 08:00AM	Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds (Business Wire)
Nov-25-24 09:00AM	Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior (Business Wire)
07:19AM	Loading…
Nov-18-24 07:19AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-14-24 04:05PM	Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results (Business Wire) -8.06%
Nov-12-24 09:00AM	Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 (Business Wire) -7.39%
Nov-04-24 10:36AM	Enveric Biosciences Announces Broad Range of Patent Issuances (Business Wire) -5.63%
Oct-15-24 08:00AM	Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 (Business Wire)
Sep-26-24 08:30AM	Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop (Business Wire) -5.78%
Sep-25-24 08:30AM	Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit (Business Wire) +7.14%
Sep-04-24 08:00AM	Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-13-24 08:00AM	Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries License for Treatment of Radiation Dermatitis and Other Conditions (Business Wire)
Aug-12-24 05:30PM	Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results (Business Wire)
Jul-25-24 08:00AM	Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally (Business Wire)
Jul-15-24 09:02AM	Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement (Business Wire)
Jul-10-24 08:00AM	Enveric Biosciences Announces Patent Granted for Drug Candidate (Business Wire) +5.82%
Jun-28-24 08:00AM	Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire)
Jun-25-24 08:00AM	Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate (Business Wire) -7.29%
08:00AM	Loading…
May-30-24 08:00AM	Enveric Biosciences to Participate in BIO International Convention 2024 (Business Wire)
May-20-24 11:54AM	ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024 (InvestorPlace)
07:45AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-15-24 06:00AM	Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results (Business Wire)
May-14-24 08:00AM	Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders (Business Wire)
May-08-24 07:00AM	Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids (Business Wire) +10.11%
May-02-24 05:50PM	Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks) +5.89%
Apr-12-24 12:00PM	What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock (Zacks) +10.95%
Apr-01-24 10:53AM	ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023 (InvestorPlace) -11.00%
Mar-26-24 07:00AM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 (Business Wire)
Mar-19-24 07:00AM	Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease (Business Wire) +8.18%
Mar-12-24 07:00AM	Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets (Business Wire) -9.09%
Feb-29-24 02:04PM	Why Is Enveric Biosciences (ENVB) Stock Up 120% Today? (InvestorPlace) +74.49%
07:00AM	Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds (Business Wire)
Feb-26-24 08:00AM	CORRECTION Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire) -13.12%
Feb-23-24 08:00AM	Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property (Business Wire) +15.29%
Feb-21-24 08:00AM	Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders (Business Wire)
Jan-03-24 08:00AM	Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series (Business Wire)
Dec-29-23 08:52AM	Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market (Business Wire) -16.67%
Dec-28-23 08:00AM	Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series (Business Wire) +19.77%
Dec-27-23 08:00AM	Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 (Business Wire)
Dec-20-23 08:00AM	Enveric Biosciences to Participate in Biotech Showcase 2024 During J.P. Morgan Week 2024 (Business Wire)
Dec-05-23 08:00AM	Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds (Business Wire) -5.10%
Nov-29-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives (Business Wire) +5.44%
Nov-27-23 08:00AM	Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry (Business Wire)
Nov-24-23 08:00AM	Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023) (Business Wire)
Nov-13-23 04:01PM	Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results (Business Wire)
Oct-31-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin (Business Wire)
Oct-20-23 08:00AM	Enveric Biosciences to Present at the Centurion One 5th Global Summit (Business Wire) -5.45%
Oct-18-23 08:00AM	Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders (Business Wire)
Oct-11-23 08:00AM	Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit (Business Wire) -8.04%
Oct-03-23 08:00AM	Enveric Biosciences Announces its Psybrary Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates (Business Wire) +20.00%
Sep-27-23 08:00AM	Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry (Business Wire) +7.94%
Sep-20-23 08:00AM	Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates (Business Wire) -6.45%
Sep-18-23 08:00AM	Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023 (Business Wire)
Sep-11-23 08:00AM	Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives (Business Wire) +7.66%
Sep-05-23 08:00AM	Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives (Business Wire)
Aug-30-23 08:00AM	Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference (Business Wire)
Aug-28-23 11:04AM	Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs (Business Wire) +7.41%
Aug-24-23 08:00AM	Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire)
Aug-21-23 08:00AM	Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program (Business Wire) +7.44%
Aug-14-23 08:00AM	Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results (Business Wire)
Jul-24-23 08:00AM	Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 (Business Wire) -10.27%
Jul-17-23 08:00AM	Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 (Business Wire)
Jun-26-23 08:00AM	Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing (Business Wire) -5.84%
Jun-12-23 08:00AM	Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (Business Wire)
Jun-07-23 08:00AM	Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) (Business Wire) -11.23%
Jun-05-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates (Business Wire)
May-30-23 08:00AM	Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023 (Business Wire) -14.58%
May-24-23 08:00AM	Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug (Business Wire) +52.70%
May-22-23 08:00AM	Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders (Business Wire) -16.38%
May-19-23 08:00AM	Enveric Biosciences to Participate in 2023 BIO International Convention in Boston (Business Wire)
May-18-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin (Business Wire) +136.18%
May-15-23 09:25AM	Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights (Business Wire)
May-02-23 07:30AM	Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month (Business Wire)
Apr-10-23 07:30AM	Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference (Business Wire)
Apr-03-23 04:05PM	Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results (Business Wire)
Mar-23-23 07:30AM	Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373 (Business Wire)
Mar-21-23 07:33AM	Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications (Business Wire)
Mar-14-23 07:30AM	Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery (Business Wire) -8.81%
Feb-28-23 07:30AM	Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.00%
Feb-23-23 07:33AM	Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Feb-22-23 07:33AM	Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference (Business Wire)
Feb-01-23 07:33AM	Enveric Biosciences to Present at the BIO CEO & Investor Conference (Business Wire)
Dec-21-22 07:30AM	Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023" (Business Wire)
Nov-28-22 07:30AM	Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders (Business Wire) -6.47%
Nov-16-22 07:30AM	Enveric Biosciences to Participate in A.G.P.s Virtual Biotech Conference (Business Wire) -5.00%
Nov-01-22 07:30AM	Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022 (Business Wire)
Oct-24-22 07:00AM	Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies (Business Wire) -6.91%
Oct-12-22 08:00AM	Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference (Business Wire)

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENVB

Enveric Biosciences Inc

Upgrade your FINVIZ experience